High Potency Recovery Supplements Combined with Increased Global Distribution Channels & New Branding Partnerships Fuels Growth Potential in the Pharmaceutical & Nutritional Supplement Industries

CORAL SPRINGS, Florida, April 15, 2015 /PRNewswire/ --

For consumers wanting to use supplements to improve their nutrition and sport performance through pharmaceutical and nutritional supplements usage plans, pharma grade products and supplements made with high-quality ingredients become top concern along with compliance and FDA regulations.  Specialty pharmaceutical & Nutritional Supplement Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), GNC Holdings, Inc. (NYSE: GNC), Vitamin Shoppe (NYSE: VSI), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and BioLife Solutions (NASDAQ: BLFS)

Axxess Pharma Inc. (OTC: AXXE) a specialty pharmaceutical and nutritional supplements company through its wholly-owned subsidiary, AllStar Health Brands Inc., is pleased to provide a shareholder update for the first quarter ending 2015.  During the first quarter of 2015, Axxess Pharma continued their global expansion of their TapouT product line, while fulfilling re-orders from the United States military. During this time, Axxess Pharma also remained focused on generating additional sales through strong marketing, increased global distribution channels, launching new, all-natural products and forming marketing partnerships with globally branded multi-million dollar and multi-billion dollar companies. Axxess Pharma also filed their financials for Year Ending 2014.

Read the full AXXE press release at http://www.financialnewsmedia.com/profiles/axxe.html

Additional accomplishments by Axxess Pharma in 2015 are: 

• Signed major promotional deal with ROC Nation. Under the agreement AllStar Health Brands partnered with Roc Nation Sports on their first three boxing events under the throne boxing banner. The first event took place at Madison Square Garden on Jan 9. Axxess Pharma and Roc Nation Sports will work together to promote the TapouT Muscle product line and throne boxing events.

• Received approval by a major Canadian distributor to sell Muscle Spray and TapouT Pain relief Towelettes to over 2,000 independent pharmacies across Canada. This represents approximately ten percent of all Canadian pharmacies.

• Received FDA approval from the United States to sell TapouT high potency Omega-3 fish oil, Muscle Growth, Muscle Recovery supplements and Turbo Blend Protein Powders in overseas markets where enhanced regulatory approvals are necessary.

• Management is now preparing to launch their latest round of all-natural products by the third quarter of 2015, which are the Ready to Drink Protein Shakes and Protein Bars. These products are expected to be the biggest sellers in 2016. The products are flavor-tested, contain high protein content, lactose free, gluten free and have less than one gram of sugar.

In other Nutritional & Pharmaceutical news & happenings around the sector are:  GNC Holdings, Inc. (NYSE: GNC) - headquartered in Pittsburgh, PA, a leading global specialty health, wellness and performance retailer, announced today the addition of three new communications partners to help drive profitable growth for the brand. The new agency partners - Consigliere (brand management/creative/advertising), CROSSMEDIA (media/communications planning) and 22squared (digital and social media) - were selected after a multiple-month review and assessment process.  "In our relentless quest to search for innovative ways to connect our customers to their best, GNC is focused on ensuring we have the right marketing partners to deliver against that promise," said Jeffrey R. Hennion, Executive Vice President, Chief Marketing and e-Commerce Officer. "Each of the agencies that competed to be a part of our team presented sound ideas, but these three companies demonstrated a deep understanding of our business, strong expertise in their respective areas and the ability to work with our highly collaborative and data driven marketing group."

Vitamin Shoppe (NYSE: VSI) Removes Products That May Contain BMPEA -  VSI announced because the health and safety of our customers is our number one priority, and out of an abundance of caution, we are immediately removing all acacia rigidula containing products, due to the concern that some of them may contain BMPEA, from our stores and website. BMPEA is a synthetic drug-like substance that should not be used in dietary supplements.  We are concerned by the findings outlined in the study published yesterday in Drug Testing and Analysis, which state that some acacia rigidula containing products may also contain BMPEA.  If these findings are confirmed by the FDA, these products should not be sold as dietary supplements.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) announced that the New Drug Application (NDA) for a liquid bendamustine hydrochloride (HCl) rapid infusion product has been accepted for filing by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal date for a decision on this NDA by the FDA is December 2015.  This NDA requests FDA approval of the rapid infusion bendamustine HCl product for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. This product candidate has received Orphan Drug Designations for both CLL and indolent B-cell NHL, and therefore may be eligible for seven years of exclusivity upon approval. The NDA is supported by data from a clinical trial completed in November 2014, which demonstrated that the rapid infusion bendamustine HCl product can be administered in ten minutes in a low-volume, 50 mL admixture.

BioLife Solutions (NASDAQ: BLFS) shares were up on heavy volume trading Tuesday after the small cap biopharmaceutical company announced preliminary first quarter financial results about a month ahead of its official earnings release date.  The company said that it generated preliminary revenue of $1.5 million which was comprised entirely of proprietary product revenue, a 30% increase over the same period last year. The propriety product revenue increase for the company was driven by a 92% year over year increase from customers in its regenerative medicine segment.  Read the full article on thestreet.com http://www.thestreet.com/story/13111818/1/biolife-solutions-blfs-stock-spikes-today-on-preliminary-financial-results.html?puc=yahoo&cm_ven=YAHOO

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/.  Follow us on Facebook:  http://www.facebook.com/financialnewsmedia and Twitter:  http://twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated two thousand dollars for news coverage of the current press release issued by Axxess Pharma Inc. by the company.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. 

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  [email protected]
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group, LLC